The principle of hemocoagulation is briefly described. Afterwards there are presented the possibilities of hematological intervention in hemorrhagic conditions in which bleeding cannot be remedied by surgical methods. Presented is a review of currently applicable transfusion products produced by blood transfusion departments (fresh frozen plasma, K-plasma, cryoprotein-cryoprecipitate, thrombocyte products, including those deleucotized and treated with ionizing radiation), their indications, contraindications, risks and potential applications. In the next part attention is paid to blood derivatives produced by the pharmaceutical industry from human plasma (concentrated hemocoagulation factors) that are currently available and applicable in the stopping of bleeding or in its prevention in patients under risk. Beside the application of blood derivatives produced from human plasma and intended mostly for substitution therapy, attention is drawn to the recombinant product NovoSven, the principle of its action and potentials of its exploitation.

        Key words: hemocoagulation – blood derivatives – recombinant product – NovoSeven – hemorrhagic conditions.